EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, X4 Pharmaceuticals's enterprise value is $2.36 Mil.
X4 Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $25.23 Mil. Therefore, X4 Pharmaceuticals's EV-to-EBITDA for today is 0.09.
The historical rank and industry rank for X4 Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
XFOR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.53 Med: 0.04 Max: 3.21
Current: 0.09
During the past 10 years, the highest EV-to-EBITDA of X4 Pharmaceuticals was 3.21. The lowest was -13.53. And the median was 0.04.
XFOR's EV-to-EBITDA is ranked better than 92.86% of 462
companies
in the Biotechnology industry
Industry Median: 10.615
vs XFOR: 0.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
X4 Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for X4 Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of X4 Pharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, X4 Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X4 Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where X4 Pharmaceuticals's EV-to-EBITDA falls into.
X4 Pharmaceuticals's current Enterprise Value is $2.36 Mil.
X4 Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
X4 Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
X4 Pharmaceuticals's share price for today is $1.43.
X4 Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of X4 Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XFOR has been successfully added to your 